Shire Plc is expecting to receive approval from the FDA for a new extended-release drug used to treat ADHD. The drug is called Intuniv, and Shire hasn't yet announced an expected release date.

"Britain's third-biggest drugmaker said it had received an 'approvable letter' from the U.S. medicines regulator for Intuniv, formerly known as Conexyn, signaling it will approve a new drug pending further information."

Shire didn't say what additional information the FDA has requested. Intuniv is a non-stimulant treatment for ADHD that is believed to have little or no risk for potential abuse or dependence.

Read more at BabyCenter.com.

Labels: medications, treatment, stimulants

Posted By: Aspen Education Group